Actualités


14

Sep 2015

MorphoSys to ramp up R&D expenditure to support slate of clinical trials

MorphoSys is set to ratchet up investment in R&D as it seeks to push candidates through late-phase trials and win the approvals that will allow it to evolve into a fully integrated biopharma company. The additional funds will support the startup of 5 new trials over the next 15 months.


6th edition of the Innovation Days in Paris – BioPharmanalyses interview

11

Sep 2015

6th edition of the Innovation Days in Paris – BioPharmanalyses interview

English Version ♦ 6th edition of the Innovation Days in Paris Hosting a human scale event in Paris with a qualified public to ensure the effectiveness of business meetings: that is the objective of the Innovation Days organized for the sixth time this year in Paris on 5 and 6 October. At the origin of this initiative, Universal Medica Group, who, facing the context of…

Read More


11

Sep 2015

Takeda bets $500M on a freshly unstealthed biotech

Japanese pharma giant Takeda is promising as much as $500 million to a previously under-wraps biotech company with some early-stage drugs that could provide a more tolerable alternative to steroid treatments.


10

Sep 2015

Ose Pharma : résultats encourageants de Phase 2 chez les patients avec métastases cérébrales traités avec Tedopi®

Ose Pharma, société biopharmaceutique qui développe des produits d’immunothérapie T spécifique contre le cancer au stade invasif, a dévoilé, hier, des résultats encourageants de survie et de réponse immune T spécifique obtenus pour les patients avec métastases cérébrales traités par Tedopi® lors de la Conférence Mondiale sur le Cancer du Poumon, qui s’est tenue à Denver aux Etats-Unis du 6 au 9 septembre 2015.



Page 9 of 38« First...7891011...2030...Last »